Fabry disease drug tested for Long-Term safety in extension study
Disease control
Ongoing
This study looks at the long-term safety of an oral medication called lucerastat for adults with Fabry disease, a rare genetic disorder. People who finished a previous 6-month study can continue taking the drug for up to 2 years. Researchers will monitor side effects and, in a su…
Phase: PHASE3 • Sponsor: Idorsia Pharmaceuticals Ltd. • Aim: Disease control
Last updated May 17, 2026 02:55 UTC